Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2013 | 07:45pm CEST

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:

http://www.monstertradingalerts.com/market-scan/?symbol=BCRX


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:

http://www.monstertradingalerts.com/market-scan/?symbol=GST

ABOUT US:

MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts
info@MonsterTradingAlerts.com
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOCRYST PHARMACEUTICALS,
03/17 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Entry into a Material ..
03/17 BIOCRYST PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Finan..
03/15 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX) Files An 8-K Other Events
03/15 BIOCRYST PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (..
03/10 BioCryst Pharmaceuticals Prices Public Offering of Common Stock
03/08 BioCryst Pharmaceuticals Commences Public Offering of Common Stock
03/01 BIOCRYST PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Alabama (March 1..
02/28 BIOCRYST PHARMACEUTICALS : Reports Positive Interim Results from its APeX-1 Tria..
02/28 BIOCRYST PHARMACEUTICALS, INC. (NASD : BCRX): A Discount Entry?
02/27 BIOCRYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04:30a WEEK 13 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/14 BioCryst Pharmaceuticals (BCRX) Presents At Barclays Global Healthcare Confer..
03/10 BioCryst prices equity offering; shares ahead 4% premarket
03/08 BioCryst readies $45M equity offering; shares slip 4% after hours
Advertisement
Financials ($)
Sales 2017 24,0 M
EBIT 2017 -45,9 M
Net income 2017 -52,1 M
Finance 2017 70,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 26,1x
Capi. / Sales 2018 29,4x
Capitalization 697 M
More Financials
Chart BIOCRYST PHARMACEUTICALS,
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Full-screen chart
Technical analysis trends BIOCRYST PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 8,33 $
Spread / Average Target -5,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jon P. Stonehouse President, Chief Executive Officer & Director
George B. Abercrombie Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab Chief Financial Officer, Treasurer, CAO & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOCRYST PHARMACEUTICA..38.78%697
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results